Form 4: NeuroPace Director Frank Fischer Granted 8,745 Stock Options

NeuroPace Inc. Director Frank M. Fischer was granted 8,745 stock options with an exercise price of $13.15, vesting over 12 months.

Summary

• Frank M. Fischer, a Director of NeuroPace Inc. (NPCE), was granted 8,745 stock options on June 6, 2025.
• The stock options have an exercise price of $13.15 per share.
• These options will vest in twelve equal consecutive monthly installments, contingent upon Mr. Fischer's continuous service through each vesting date.
• The options are exercisable as they vest and have an expiration date of June 5, 2035.
• Following this transaction, Mr. Fischer beneficially owns 8,745 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management's interests with shareholders and incentivizes long-term performance. It is a routine compensation event and not indicative of major operational news or financial distress.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The vesting schedule encourages the director's continuous service and commitment to NeuroPace Inc. over the next year.

Negatives

• No direct negatives are apparent from this routine stock option grant, which is a standard component of executive and director compensation.

Risks

• The value of the granted stock options is contingent on NeuroPace Inc.'s common stock price exceeding the exercise price of $13.15 per share.
• If the company's stock price does not appreciate above the exercise price, the options may not be exercised and could expire worthless, resulting in no financial benefit to the holder.

Future Outlook

The grant of stock options with a multi-month vesting schedule suggests an expectation of continued growth and value creation for NeuroPace Inc. over the coming year, aligning the director's incentives with long-term shareholder value.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, as it is a transactional report detailing changes in beneficial ownership.

Industry Context

Stock option grants are a common and widely accepted component of compensation packages for directors and executives across various industries, particularly in the medical technology and healthcare sectors. This practice aims to attract and retain qualified talent while aligning their financial interests with the company's performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice for publicly traded companies, including those in the medical device sector like NeuroPace. Companies such as Medtronic (MDT) and Boston Scientific (BSX) also routinely use equity grants for their directors.
• The exercise price of $13.15, typically set at the market price on the grant date, is standard for such grants.
• The 12-month monthly vesting schedule is a common approach for director equity, though some companies may opt for longer vesting periods (e.g., 3-4 years) or annual vesting. This specific schedule encourages continuous engagement over the short-to-medium term.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The granted stock options will vest in twelve equal consecutive monthly installments, subject to Frank M. Fischer's continuous service to NeuroPace Inc.

Key Dates

Recommendation

Keywords

NeuroPace Inc., NPCE, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Frank M. Fischer